Aditxt's (Nasdaq: ADTX) Adimune™ Program Has Initiated the Manufacturing Process of Immunotherapeutic Drug Candidate, ADI™-100 in Preparation for Planned Psoriasis First-in-Human Trials
businesswire.com
news
2022-10-21 00:00:00

October 21, 2022 09:00 AM Eastern Daylight Time RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX) ('Aditxt' or the 'Company'), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announces that its program Adimune™ has initiated the GMP manufacturing of drug candidate ADI™-100 as a key milestone toward its goal to begin first-in-human trials during the second half of 2023. Pending regulatory approvals, these trials will be performed in autoimmune diseases, with psoriasis as the first indication to be studied.
